Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-16 4:00 pm Sale |
2024-02-14 | 13D | Theseus Pharmaceuticals, Inc. THRX |
TANG CAPITAL PARTNERS LP | 100 100.000% |
-3,254,926 (-100.00%) |
Filing History |
| 2024-02-13 12:36 pm Sale |
2023-12-31 | 13G | Theseus Pharmaceuticals, Inc. THRX |
Frazier Life Sciences Public Fund, L.P. | 0 0.000% |
-2,248,194 (Position Closed) |
Filing History |
| 2024-01-12 06:02 am Unchanged |
2024-01-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
TANG CAPITAL PARTNERS LP | 3,255,026 7.300% |
0 (Unchanged) |
Filing History |
| 2023-12-28 06:00 am Purchase |
2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
TANG CAPITAL PARTNERS LP | 3,255,026 7.300% |
153,420 (+4.95%) |
Filing History |
| 2023-12-27 4:43 pm Unchanged |
2023-12-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.100% |
0 (Unchanged) |
Filing History |
| 2023-11-24 4:28 pm Unchanged |
2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.100% |
0 (Unchanged) |
Filing History |
| 2023-11-24 4:23 pm Unchanged |
2023-11-22 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.400% |
0 (Unchanged) |
Filing History |
| 2023-11-24 1:49 pm Purchase |
2023-11-14 | 13D | Theseus Pharmaceuticals, Inc. THRX |
TANG CAPITAL PARTNERS LP | 3,101,606 7.000% |
3,101,606 (New Position) |
Filing History |
| 2023-08-10 08:19 am Sale |
2023-08-09 | 13G | Theseus Pharmaceuticals, Inc. THRX |
FMR LLC | 1,194 0.002% |
-2,497,161 (-99.95%) |
Filing History |
| 2023-07-19 4:12 pm Purchase |
2023-07-17 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,713,600 40.700% |
479,932 (+2.78%) |
Filing History |
| 2023-07-19 2:41 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 5,494,621 12.600% |
700,000 (+14.60%) |
Filing History |
| 2023-03-14 4:19 pm Purchase |
2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 17,233,668 39.600% |
395,000 (+2.35%) |
Filing History |
| 2023-02-09 12:39 pm Sale |
2023-02-09 | 13G | Theseus Pharmaceuticals, Inc. THRX |
FMR LLC | 2,498,355 6.453% |
-694,308 (-21.75%) |
Filing History |
| 2023-01-23 12:17 pm Purchase |
2023-01-13 | 13G | Theseus Pharmaceuticals, Inc. THRX |
Frazier Life Sciences Public Fund, L.P. | 2,248,194 5.800% |
2,248,194 (New Position) |
Filing History |
| 2023-01-03 4:36 pm Purchase |
2022-12-29 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,794,621 12.400% |
500,000 (+11.64%) |
Filing History |
| 2022-12-12 08:41 am Sale |
2022-12-09 | 13G | Theseus Pharmaceuticals, Inc. THRX |
FMR LLC | 3,192,663 8.246% |
-2,256,006 (-41.40%) |
Filing History |
| 2022-06-13 4:24 pm Purchase |
2022-06-09 | 13D | Theseus Pharmaceuticals, Inc. THRX |
Foresite Capital Fund V L.P. | 4,294,621 11.100% |
613,069 (+16.65%) |
Filing History |
| 2022-02-09 10:01 am Purchase |
2022-02-08 | 13G | Theseus Pharmaceuticals, Inc. THRX |
FMR LLC | 5,448,669 14.078% |
1,494,953 (+37.81%) |
Filing History |
| 2021-11-18 5:10 pm Unchanged |
2021-11-15 | 13D | Theseus Pharmaceuticals, Inc. THRX |
ORBIMED ADVISORS LLC | 16,838,668 43.500% |
0 (Unchanged) |
Filing History |
| 2021-11-10 12:24 pm Purchase |
2021-11-09 | 13G | Theseus Pharmaceuticals, Inc. THRX |
FMR LLC | 3,953,716 10.534% |
3,953,716 (New Position) |
Filing History |